Thinly traded nano cap Immuron Limited (NASDAQ:IMRN) jumped 27% premarket on increased volume in reaction to its announcement that
collaborator Naval Medical Research Center (NMRC) has requested a
pre-IND meeting with the FDA regarding an IND for a new oral therapeutic
to treat Campylobacter (campylobacteriosis) and E. Coli infections.
NMRC plans to file an IND later this year and launch Phase 2 studies in H1 2021.
Immuron currently markets two products: Protectyn, a formulation of hyperimmune bovine colostrum designed to remove harmful bacteria and their toxins from the gut, and Travelan, an over-the-counter immune supplement to reduce the risk of diarrhea and reduce symptoms of minor GI disorders.
https://seekingalpha.com/news/3581452-immuron-up-big-on-advancement-of-oral-therapeutic-for-bacterial-infections
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.